ASX:PKSPKS Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PKS Holdings Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines PKS Holdings Limited, a healthcare technology company, develops and commercializes proprietary subscription based clinical decision support (CDS) systems that automates the human decision-making process in healthcare organizations in Australia and internationally. The company offers RippleDown Expert, an CDS system that provides real-time patient monitoring, alerting, data mining, and reporting capability; and RippleDown Auditor, a knowledge based system that allows various departments within a laboratory, including data entry, billing, and specimen reception to audit data in real-time. It serves customers through direct sales and channel partners. The company was formerly known as QPro Holdings Limited. PKS Holdings Limited was founded in 1996 and is based in Sydney, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for PKS. Previous Next 0.0 Community Rank Outperform VotesPKS has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPKS has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about PKS and other stocks. Vote “Outperform” if you believe PKS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PKS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPKS does not currently pay a dividend.Dividend GrowthPKS does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PKS insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$19,890.00 in company stock and sold A$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Health Information Services Sub-IndustryN/A SectorMedical Current SymbolASX:PKS Previous Symbol CUSIPN/A CIKN/A Webwww.pks.com.au Phone61 2 8072 1400Debt Debt-to-Equity Ratio0.54 Current Ratio6.03 Quick Ratio6.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.20 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.17 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive PKS News and Ratings via Email Sign-up to receive the latest news and ratings for PKS and its competitors with MarketBeat's FREE daily newsletter. PKS (ASX:PKS) Frequently Asked Questions Has PKS been receiving favorable news coverage? Media stories about PKS stock have been trending very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PKS earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutPKS. Who are some of PKS's key competitors? Some companies that are related to PKS include CannaOne Technologies (CNNA), CannaOne Technologies (CNONF), Corum Group (COO), eWELLNESS HEALTHCARE (EWLL), NMC Health (PMCUF), Omnicell (MTHRF), Tali Digital (TD1), US-China Biomedical Technology (UCBB) and ZoomMed (ZMD). View all competitors. Who are PKS's key executives? PKS's management team includes the following people: Mr. Ronald Andre Van Der Pluijm, MD, CEO & DirectorMr. Andrew William Bursill C.A., B.Agr.Ec., CA, Chief Financial Officer (Age 49)Dr. Lindsay Peters, Chief Technical OfficerMr. Michael Reakes, Gen. Mang.Ms. Maggie Niewidok, Company Sec. What is PKS's stock symbol? PKS trades on the ASX under the ticker symbol "PKS." How big of a company is PKS? PKS has a market capitalization of $0.00 and generates $2.20 million in revenue each year. What is PKS's official website? The official website for PKS is www.pks.com.au. How can I contact PKS? The company can be reached via phone at 61 2 8072 1400. This page was last updated on 6/4/2020 by MarketBeat.com Staff
